UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14276-e14276

2019

Volltextzugriff (PDF)

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20573-e20573

2018

Volltextzugriff (PDF)

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13120-e13120

2024

Volltextzugriff (PDF)

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Journal of clinical oncology, 2022-09, Vol.40 (27), p.JCO2102641-3171

2022

Volltextzugriff (PDF)

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20689-e20689

2019

Volltextzugriff (PDF)

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14711-e14711

2019

Volltextzugriff (PDF)

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20083-e20083

2019

Volltextzugriff (PDF)

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16097-e16097

2022

Volltextzugriff (PDF)

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16290-e16290

2023

Volltextzugriff (PDF)

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2576-2576

2023

Volltextzugriff (PDF)

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1047-1047

2024

Volltextzugriff (PDF)

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3154-3154

2024

Volltextzugriff (PDF)

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8533-8533

2024

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9562-9562

2024

Volltextzugriff (PDF)

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23192-e23192

2017

Volltextzugriff (PDF)

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9116-9116

2022

Volltextzugriff (PDF)

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18502-e18502

2019

Volltextzugriff (PDF)

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA1013-LBA1013

2023

Volltextzugriff (PDF)

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2536-2536

2023

Volltextzugriff (PDF)

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9081-9081

2023

Volltextzugriff (PDF)

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3547-3547

2023

Volltextzugriff (PDF)

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3593-3593

2024

Volltextzugriff (PDF)

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.8516-8516

2024

Volltextzugriff (PDF)

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9096-9096

2022

Volltextzugriff (PDF)

Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9101-9101

2022

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

ThemaLung Neoplasms - Drug Therapy

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Original Reports
(1)

Kollektion

Menü

Weitere Dienste

Einstellungen

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA -mutated, HR+/HER2- advanced breast cancer

A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study

Amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)

Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study

Aktive Filter

Suchergebnisse filtern